


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7/27/06

Signature:

Jennifer Tardiff
(Jennifer Tardiff)



Docket No.: ALXN-P02-089
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Figdor et al.

Application No.: 10/625202

Confirmation No.: 1242

Filed: July 23, 2003

Art Unit: 1648

For: COMPOSITION AND METHOD FOR
MODULATING DENDRITIC CELL-T CELL
INTERACTION

Examiner: M. G. Hill

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ALXN-P02-089. A duplicate copy of this paper is enclosed.

Dated: July 27, 2006

Respectfully submitted,

By


Jennifer Holmes, Ph.D., J.D.

Registration No.: 46,778

FISH & NEAVE IP GROUP, ROPES & GRAY

LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/625202
				Filing Date	July 23, 2003
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1648
				Examiner Name	M. G. Hill
Sheet	1	of	2	Attorney Docket Number	ALXN-P02-089

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-6,605,279-B2	08-12-2003	Freeman et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Amersdorfer et al., <i>Infection and Immunity</i> , 65, pp. 3743-3752 (1997).		
	CB	Andre et al., <i>Journal of Virology</i> , 72(2), pp. 1497-1503 (1998).		
	CC	Baribaud, Frederic, et al., "Functional and Antigenic Characterization of Human, Rhesus Macaque, Pigtailed Macaque, and Murine DC-SIGN," <i>Journal of Virology</i> , 75(21), pp. 10281-10289 (2001).		
	CD	Kataoka et al., <i>Cancer Research</i> , 38(5), pp. 1202-1207 (1987) – Abstract only from Biosis database.		
	CE	Cohen, <i>Science</i> , 287, p. 1567 (2000).		
	CF	Engering, Anneke, et al., "The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells," <i>J. of Immun.</i> , 168, pp. 2118-2126 (2000).		
	CG	Feinberg, Hadar, et al., "Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and SC-SIGNR," <i>Science</i> , 294, pp. 2163-2166 (2001) (with Supplementary Material published electronically on the <i>Science</i> website, 6 pgs.).		
	CH	Geijtenbeek, Teunis, B.H., et al., "Identification of DC-SIGN, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses," <i>Cell</i> , 100, pp. 575-585 (2000).		
	CI	Geijtenbeek, Teunis, B.H., et al., <i>Cell</i> , 100, pp. 587-597 (2000).		
	CJ	Geijtenbeek, et al., "Identification of Different Binding Sites in the Dendritic Cell-Specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1," <i>J. Biol. Chem.</i> , 277(13), pp. 11314-11320 (2002).		
	CK	Gruber, Andreas, et al., "Functional Aspects of Binding of Monoclonal Antibody DCN46 to DC-SIGN on Dendritic Cells," <i>Immunology Letters</i> , 84, pp. 103-108 (2002).		
	CL	Harlow and Lane, <i>Antibodies: A Laboratory Manual</i> , 1988 Cold Spring Harbor Laboratory, pages 141-142.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/625202
				Filing Date	July 23, 2003
				First Named Inventor	Carl Gustav Figdor
				Art Unit	1648
				Examiner Name	M. G. Hill
Sheet	2	of	2	Attorney Docket Number	ALXN-P02-089

	CM	Janeway, Charles, A., Jr., et al., <u>Immunobiology</u> , (5th ed.), Garland Publishing, New York, p.691 (2001).	
	CN	Pohlmann, Stefan, et al., "DC-SIGN Interactions with Human Immunodeficiency Virus Type 1 and 2 and Simian Immunodeficiency Virus," <i>J. of Virology</i> , 75(10), pp. 4664-4672 (2001).	
	CO	Steinman, <i>Cell</i> , 287, pp. 491-494 (2000).	
	CP	Toda, et al., <i>Immunology</i> , 92, pp. 111-117 (1997).	
	CQ	Vakeva, Antti, P., et al., "Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion," <i>Circulation</i> , 97, pp. 2259-2267 (1998).	
	CR	Woodle, E.S., et al., <i>Transplantation</i> , 68, pp. 608-616 (1999).	
	CS	FDA Approves Second Indication for Monoclonal Antibody, June 28, 1993, printed on November 12, 2004 from http://www.fda.gov/bbs/topics/ANSWERS/ANS00506.html , June 28, 1993.	
	CT	Product Information for Affinity Purified anti-human CD209 (DC-SIGN) antibody, from eBioscience, printed on January 5, 2004 from http://www.ebioscience.com/ebioscience/specs/antibody_14/14-2099.htm	
	CU	Product information for CDN46, Purified Mouse Anti-Human Monoclonal Antibody, BD PharMingen Technical Data Sheet, BD Biosciences Product Information sheet, Catalog Number 551186, 05/01/01.	
	CV	Package insert for Orthoclone OKT3 Sterile Solution (murumonab-CD3) from Ortho Biotech Products LP, Raritan, NJ, Revised March 2001.	
	CW	Sequence Alignment of Curtis et al., PNAS 89: 8356-8360 (1992) with SEQ ID NO: 2 from U.S.S.N. 09/719,961.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/625202

Attorney Docket No.: ALXN-P02-089

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 27, 2006
Date

Signature

Jennifer Tardiff

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (24 References) (CA-CW) (2 pages) with
Certificate of Mailing
Information Disclosure Statement
This postcard receipt